1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck's Keytruda First-Line Improves Esophageal Cancer Survival

Regardless Of Histology, When Combined With Chemotherapy

 
• By John Davis

Merck & Co is working hard to extend the indications for Keytruda, and reports the checkpoint inhibitor significantly improves overall survival and PFS when combined with chemotherapy in the first-line treatment of metastatic esophageal cancer.    

Waterfall
• Source: Shutterstock

Merck & Co., Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab), combined with chemotherapy, has improved the two primary endpoints, overall survival and progression-free survival (PFS), when used first line for the treatment of locally advanced or metastatic esophageal cancer, according to the results of an interim analysis of the pivotal Phase III KEYNOTE-590 trial.

Further details of the clinical benefit associated with Keytruda in earlier lines of therapy than the currently approved esophageal cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

More from R&D

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.